PARSIPPANY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal third quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, August 8, 2023.
Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.
A webcast replay of the call will be available beginning at 11:00 a.m. ET on August 8, 2023, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
| Contacts: | |
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$14.62 |
| Daily Change: | -0.43 -2.86 |
| Daily Volume: | 318,169 |
| Market Cap: | US$843.570M |
September 03, 2024 August 09, 2024 February 09, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
